Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지

Current Status of the Diagnosis and Management of Pancreatic Neuroendocrine Tumors in Japan

  • Tetsuhide Ito (Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University) ;
  • Masami Miki (Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University) ;
  • Keijiro Ueda (Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University) ;
  • Lingaku Lee (Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University) ;
  • Ken Kawabe (Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University) ;
  • Hisato Igarashi (Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University) ;
  • Nao Fujimori (Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University) ;
  • Kazuhiko Nakamura (Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University) ;
  • Kohei Yasunaga (Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University) ;
  • Robert T. Jensen (Digestive Diseases Branch, National Institutes of Diabetes, Digestive and Kidney Diseases, National Institutes of Health) ;
  • Takao Ohtsuka (Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University) ;
  • Yoshihiro Ogawa (Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University)
  • Received : 2016.10.28
  • Accepted : 2016.12.23
  • Published : 2016.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

The epidemiology of pancreatic neuroendocrine neoplasms (PNENs) in Asia has been clarified through epidemiological studies, including one conducted in Japan, and subsequently another in South Korea. As endoscopic ultrasonography (EUS) has become more widely accessible, endoscopic ultrasound-fine needle aspiration (EUS-FNA) has been performed in pancreatic tumors for which the clinical course was only monitored previously. This has enabled accurate diagnosis of pancreatic tumors based on the 2010 WHO classification; as a result, the number of patients with an accurate diagnosis has increased. Although surgery has been the standard therapy for PNENs, new treatment options have become available in Japan for the treatment of advanced or inoperable PNENs; of particular note is the recent introduction of molecular target drugs (such as everolimus and sunitinib) and streptozocin. Treatment for progressive PNENs needs to be selected for each patient with consideration of the performance status, degree of tumor differentiation, tumor mass, and proliferation rate. Somatostatin receptor (SSTR)-2 is expressed in many patients with neuroendocrine tumor. Somatostatin receptor scintigraphy (SRS), which can visualize SSTR-2 expression, has been approved in Japan. The SRS will be a useful diagnostic tool for locating neuroendocrine neoplasms, detecting distant metastasis, and evaluating therapy outcomes. In this manuscript, we review the latest diagnostic methods and treatments for PNENs.

Keywords

References

  1. Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010;45:234-243.
  2. Ito T, Igarashi H, Kazuhiko K, Sasano H, Okusaka T, Takano K, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol 2015;50:58-64.
  3. Cho JH, Ryu JK, Song SY, Hwang JH, Lee DK, Woo SM, et al. Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors: A Retrospective Nationwide Multicenter Study in South Korea. Pancreas 2016;45:941-946.
  4. Bosman FT, Carneiro F, Hruban RH et al. WHO classification of tumours of the digestive system. Lyon: IARC; 2010.
  5. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol 2013;24:152-160.
  6. Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, et al. Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas Are Genetically Similar and Distinct from Well- differentiated Pancreatic Neuroendocrine Tumors. Am J Surg Pathol 2012;36:173-184.
  7. Ito T, Igarashi H, Uehara H, Jensen RT. Pharmacotherapy of Zollinger-Ellison syndrome Expert Opin Pharmacother. 2013;14(3):307-321.
  8. Ito T, Igarashi H, Jensen RT. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol 2012;47(9):941-960.
  9. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker R V, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
  10. Hijioka M, Ito T, Igarashi H, Fujimori N, Lee L, Nakamura T, et al. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors. Cancer Sci. 2014;105:1464-1471.
  11. Kanakis G, Kaltsas G. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract Res Clin Gastroenterol 2012;26:791-802.
  12. Jensen RT, Cadiot G, Brandi ML, De Herder WW, Kaltsas G, Komminoth P, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: Functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012;95:98-119.
  13. Service FJ, Natt N. The prolonged fast. J Clin Endocrinol Metab 2000;85:3973-3974.
  14. Ueda K, Kawabe K, Lee L, et al. Diagnostic Performance of 48-Hour Fasting Test and Insulin Surrogates in Patients with Suspected Insulinoma. Pancreas, in Press. 2016.
  15. Imamura M. Recent standardization of treatment strategy for pancreatic neuroendocrine tumors. World J Gastroenterol 2010;16:4519-4525.
  16. Fujimori N, Osoegawa T, Lee L, Tachibana Y, Aso A, Kubo H, et al. Efficacy of endoscopic ultrasonography and endoscopic ultrasonography-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors. Scand J Gastroenterol 2016;51:245-252.
  17. Hasegawa T, Yamao K, Hijioka S, Bhatia V, Mizuno N, Hara K, et al. Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors. Endoscopy 2014;46:32-38.
  18. O'Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O'Connor J, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Biochemical markers. Neuroendocrinology 2009;90:194-202.
  19. Bodei L, Sundin A, Kidd M, et al. The status of neuroendocrine tumor imaging: from darkness to light? Neuroendocrinology 2015;101:1-17.
  20. Ito T, Jensen RT. Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies. Int J Endo Oncol 2016;3:53-66.
  21. Kwekkeboom DJ, Kam BL, Van Essen M, Teunissen JJM, Van Eijck CHJ, Valkema R, et al. Somatostatin receptorbased imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010;17:R53-73.
  22. Tumors N, Lombard-bohas C, Yao JC, Hobday T, Cutsem E Van, Wolin EM, et al. Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic A Subgroup Analysis of the Phase III RADIANT-3 Trial. Pancreas 2015;44:181-189.
  23. Yao JC, Pavel M, Lombard-Bohas C, Van Cutsem E, Voi M, Brandt U, et al. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. J. Clin. Oncol. 2016. [Epub; Published Aahead of Print].
  24. Ito T, Okusaka T, Ikeda M, Igarashi H, Morizane C, Nakachi K, et al. Everolimus for advanced pancreatic neuroendocrine tumours: A subgroup analysis evaluating japanese patients in the radiant-3 trial. Jpn J Clin Oncol 2012;42:903-911.
  25. Raymond E, Dahan L, Raoul J-L, Bang Y-J, Borbath I, Lombard-Bohas C, et al. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. N Engl J Med 2011;364:501-513.
  26. Ito T, Okusaka T, Nishida T, Yamao K, Igarashi H, Morizane C, et al. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs. 2013;31:1265-1274.
  27. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozotocin-doxorubicin, streptozotocin-fluorouracil or chlorozotocin in the treatment of advanced islet cell carcinoma. Eng J Med 1992;326:519-523.
  28. Aoki T, Kokudo N, Komoto I, Takaori K, Kimura W, Sano K, et al. Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan. J Gastroenterol 2015;50:769-775.
  29. Lee L, Igarashi H, Fujimori N, Hijioka M, Kawabe K, Oda Y, et al. Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: A single-center retrospective study. Jpn J Clin Oncol 2015;45:1131-1138.
  30. Ito T. Highlights of topic "Pancreatic neuroendocrine tumors update". J Hepatobiliary Pancreat Sci 2015;22:573.
  31. Ito T, Hijioka S, Masui T, Kasajima A, Nakamotp Y, Kobayashi N, et al. Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan. J Gastroenterol. 2016 Aug 18. [Epub ahead of print]
  32. Guideline for pancreatic and gastroenteric neuroendocrine tumor. Edited by Japan Neuroendocrine Tumor Society. ISBN 978-4-307-20339-5, 2015. (in Japanese)